Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Membranous nephropathy (MN) is a major cause of nephrotic syndrome in adults. This study aimed to evaluate the effect of rituximab (RTX) in patients with idiopathic MN (iMN) who have a high risk of progression. Methods: We retrospectively analyzed data of 13 patients with iMN, who received RTX treatments from January 2014 to July 2020. RTX was indicated in patients with iMN with severe proteinuria and decreasing estimated glomerular filtration rate (eGFR) in the previous 6 months despite other immunosuppressive therapies. Results: The patients were predominantly males (n = 11) and with a mean age of 55.3 years; median eGFR, 37.0 mL/ min/1.73 m2 (interquartile range [IQR], 26.3 to 66.5); serum albumin level, 2.6 g/dL (IQR, 1.9 to 3.1); and spot urine protein- to-creatinine ratio at baseline, 6.6 g/g (IQR, 5.7 to 12.9). In a median follow-up of 22 months, eight patients (61.5%) achieved complete or partial remission. In responder group (n = 8), median eGFR increased from 31.5 to 61.5 mL/min/1.73 m2 (p = 0.049) and serum albumin level increased from 2.3 to 4.2 g/dL (p = 0.017) from RTX initiation to last follow-up. Antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) was positive in six among seven tested patients, which markedly decreased in the responder group. There were no adverse events after RTX. Conclusions: This study suggests that RTX is a safe and effective treatment option for patients with iMN who have a high risk of progression. Individualized therapy based on anti-PLA2R-Ab titer would be needed for better outcomes.
Abstract
Background/Aims: Membranous nephropathy (MN) is a major cause of nephrotic syndrome in adults. This study aimed to evaluate the effect of rituximab (RTX) in patients with idiopathic MN (iMN) who have a high risk of progression. Methods: We retrospectively analyzed data of 13 patients with iMN, who received RTX treatments from January 2014 to July 2020. RTX was indicated in patients with iMN with severe proteinuria and decreasing estimated glomerular filtration rate (eGFR) in the previous 6 months despite other immunosuppressive therapies. Results: The patients were predominantly males (n = 11) and with a mean age of 55.3 years; median eGFR, 37.0 mL/ min/1.73 m2 (interquartile range [IQR], 26.3 to 66.5); serum albumin level, 2.6 g/dL (IQR, 1.9 to 3.1); and spot urine protein- to-creatinine ratio at baseline, 6.6 g/g (IQR, 5.7 to 12.9). In a median follow-up of 22 months, eight patients (61.5%) achieved complete or partial remission. In responder group (n = 8), median eGFR increased from 31.5 to 61.5 mL/min/1.73 m2 (p = 0.049) and serum albumin level increased from 2.3 to 4.2 g/dL (p = 0.017) from RTX initiation to last follow-up. Antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) was positive in six among seven tested patients, which markedly decreased in the responder group. There were no adverse events after RTX. Conclusions: This study suggests that RTX is a safe and effective treatment option for patients with iMN who have a high risk of progression. Individualized therapy based on anti-PLA2R-Ab titer would be needed for better outcomes.
참고문헌 (26)
- Austin HA 3rd, "NIH conference. Membranous nephropathy", Ann Intern Med, 116, pp.672~682 (1992)
- Liu Y, "Renoprotective effects of isoliquiritin against cationic bovine serum albumin-induced membranous glomerulonephritis in experimental rat model through its anti-oxidative and anti-inflammatory properties", Drug Des Devel Ther, 13, pp.3735~3751 (2019)
- Couser WG, "Primary membranous nephropathy", Clin J Am Soc Nephrol, 12, pp.983~997 (2017)
- van de Logt AE, "The anti-PLA2R antibody in membranous nephropathy : what we know and what remains a decade after its discovery", Kidney Int, 96, pp.1292~1302 (2019)
- Dai H, "Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy : an updated meta-analysis", Sci Rep, 5, pp.8803~ (2015)
- Svobodova B, "Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy", Nephrol Dial Transplant, 28, pp.1839~1844 (2013)
- McQuarrie EP, "Idiopathic membranous nephropathy and nephrotic syndrome : outcome in the era of evidence-based therapy", Nephrol Dial Transplant, 27, pp.235~242 (2012)
- Huh H, "Factors affecting the long-term outcomes of idiopathic membranous nephropathy", BMC Nephrol, 18, pp.104~ (2017)
- Kerjaschki D, "Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy(Heymann nephritis)", J Am Soc Nephrol, 7, pp.2518~2526 (1996)
- Cohen CD, "CD20-positive infiltrates in human membranous glomerulonephritis", J Nephrol, 18, pp.328~333 (2005)
- Bomback AS, "Rituximab therapy for membranous nephropathy : a systematic review", Clin J Am Soc Nephrol, 4, pp.734~744 (2009)
- Remuzzi G, "Rituximab for idiopathic membranous nephropathy", Lancet, 360, pp.923~924 (2002)
- Cravedi P, "Rituximab in membranous nephropathy : not all studies are created equal", Nephron, 135, pp.46~50 (2017)
- Wang X, "Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort", Nephrol Dial Transplant, 33, pp.1558~1563 (2018)
- Kidney disease : improving global outcomes(KDIGO)glomerulonephritis work group, "KDIGO clinical practice guideline for glomerulonephritis", Kidney Int Suppl, 2, pp.139~274 (2012)
- Ruggenenti P, "Rituximab in idiopathic membranous nephropathy", J Am Soc Nephrol, 23, pp.1416~1425 (2012)
- Fiorentino M, "Treatment with rituximab in idiopathic membranous nephropathy", Clin Kidney J, 9, pp.788~793 (2016)
- Dahan K, "Rituximab for severe membranous nephropathy : a 6-month trial with extended follow-up", J Am Soc Nephrol, 28, pp.348~358 (2017)
- Hanset N, "Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD", Kidney Int Rep, 5, pp.331~338 (2019)
- Jae YoungYoon, "Two cases of idiopathic membranous nephropathy treated with rituximab", Kidney Research and Clinical Practice, 32(3), pp.138~141 (2013), 대한신장학회
- Hwang SD, "Effect of rituximab used as induction in patients with ABO mismatch kidney transplant : a systematic review and meta-analysis", Transplant Proc, 52, pp.3125~3128 (2020)
- van den Brand JAJG, "Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy", J Am Soc Nephrol, 28, pp.2729~2737 (2017)
- Maifata SM, "Primary membranous glomerulonephritis : the role of serum and urine biomarkers in patient management", Biomedicines, 7, pp.86~ (2019)
- Burbelo PD, "Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy", J Am Soc Nephrol, 31, pp.208~217 (2020)
- Radice A, "Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor(PLA2R)for monitoring disease activity in idiopathic membranous nephropathy(IMN)", Autoimmun Rev, 15, pp.146~154 (2016)
- Beck LH Jr, "Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy", J Am Soc Nephrol, 22, pp.1543~1550 (2011)